Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21358321 | 0.86 | ALDH1A1 (0.39) | KDM4EALDH1A1ALOX15JAK1 | |
| SCHEMBL29460270 | 0.77 | ACHE (0.43) | KDM4EALDH1A1 | |
| SCHEMBL633200 | 0.77 | ACHE (0.43) | KDM4EALDH1A1 | |
| SCHEMBL21358501 | 0.76 | GPR119 (0.35) | — | |
| Hydrochloric Acid SCHEMBL19996108 | 0.76 | ACHE (0.41) | KDM4EALDH1A1 | |
| SCHEMBL8377244 | 0.74 | HSD11B1 (0.37) | KDM4EALDH1A1ALOX15POLBJAK1 | |
| SCHEMBL21358497 | 0.73 | SMYD3 (0.31) | — | |
| SCHEMBL3308909 | 0.72 | MAPK1 (0.42) | KDM4EALDH1A1ALOX15POLBJAK1 | |
| SCHEMBL21358394 | 0.71 | POLB (0.49) | ALDH1A1POLB | |
| SCHEMBL30009830 | 0.70 | JAK1 (0.30) | JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106329-A1 | BICYCLIC ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B V (US) | 2022-04-07 | — | — | US | disclosed |
| US-11230555-B2 | Bicyclic RORγ modulators | ESCALIER BIOSCIENCES B.V. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20210053987-A1 | BICYCLIC ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2021-02-25 | — | — | US | disclosed |
| EP-3765009-A1 | BICYCLIC ROR-GAMMA MODULATORS | Escalier Biosciences, BV (US) | 2021-01-20 | — | — | EP | disclosed |
| WO-2019177996-A1 | BICYCLIC ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. (US) | 2019-09-19 | — | — | WO | disclosed |
| US-20140113005-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-04-24 | — | — | US | disclosed |
| US-8410112-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410112-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410112-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120040020-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040020-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040020-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2370424-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010054398-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113005-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK2, CHEK1 | KDM4E 2868/4885ALDH1A1 3958/4885ALOX15 4046/4885 |
| US-20120040020-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK2, CHEK1 | KDM4E 2868/4885ALDH1A1 3958/4885ALOX15 4046/4885 |
| US-11230555-B2 | Bicyclic RORγ modulators | RORC, RORA, RORB | KDM4E 3213/4885ALDH1A1 403/4885ALOX15 931/4885 |
| US-20210053987-A1 | BICYCLIC ROR-GAMMA MODULATORS | RORA, RORC, RORB | KDM4E 3482/4885ALDH1A1 287/4885ALOX15 1737/4885 |
| US-20220106329-A1 | BICYCLIC ROR-GAMMA MODULATORS | RORA, RORC, RORB | KDM4E 3482/4885ALDH1A1 287/4885ALOX15 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.